How Has the Keytruda Market Evolved Historically and What is its Current Size?
The keytruda market has seen considerable growth due to a variety of factors.
• The Keytruda market has seen significant growth in recent years, expected to increase from $21.6 billion in 2024 to $23.8 billion in 2025, growing at a CAGR of 10.2%.
This growth can be attributed to improved patient outcomes, greater adoption of immunotherapy, advances in research and development, better patient compliance, and a rising uptake of Keytruda.
What is the Forecasted Market Size and CAGR for the Keytruda Market?
The keytruda market is expected to maintain its strong growth trajectory in upcoming years.
• The Keytruda market is forecasted to expand to $34.61 billion by 2029, with a CAGR of 9.8%.
The growth is driven by expanding therapeutic indications, emerging markets, the increasing incidence of cancer, higher healthcare spending, and growing demand for precision medicine. Trends contributing to this growth include the rise in demand for targeted therapies, advances in immunotherapy, improvements in diagnostic technologies, and continued progress in cancer research.
What Key Factors and Trends Are Driving The Growth Keytruda Market?
The rising number of cancer cases is anticipated to drive the growth of the Keytruda market. Cancer involves the abnormal growth of cells and is influenced by factors like genetics, lifestyle, and environment. Keytruda (pembrolizumab) works by boosting the immune system's ability to target and eliminate cancer cells. This treatment has shown significant progress in helping patients with advanced cancers. In January 2024, the American Cancer Society reported that the number of cancer cases in the U.S. rose to 2,001,140 in 2024, up from 1,958,310 in 2023, marking a 2.19% increase. As such, the growing cancer prevalence contributes to Keytruda market growth.
What Are The Market Segments In The Keytruda Market?
The keytruda market covered in this report is segmented –
1) By Cancer Type: Melanoma, Lung Cancer, Head And Neck Cancer, Hodgkin Lymphoma, Stomach Cancer, Urothelial Carcinoma
2) By Payer Type: Commercial, Medicare, Medicaid
3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies
Subsegments:
1) By Melanoma: Advanced Or Unresectable Melanoma, Adjuvant Treatment For Melanoma
2) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)
3) By Head And Neck Cancer: Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Recurrent Or Metastatic Head And Neck Cancer
4) By Hodgkin Lymphoma: Classical Hodgkin Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma
5) By Stomach Cancer: Advanced Or Metastatic Gastric Cancer, Esophagogastric Junction Cancer
6) By Urothelial Carcinoma: Advanced Or Metastatic Urothelial Carcinoma, Muscle-Invasive Bladder Cancer
Pre-Book The Keytruda Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Influencing The Growth Of The Keytruda Market?
Prominent enterprises within the Keytruda market are forging ahead with the creation of cutting-edge products, including pembrolizumab, to enhance the available treatment choices. Pembrolizumab, a monoclonal antibody medication falling under the immune checkpoint inhibitors drug classification, is sold under the Keytruda brand name. It targets and inhibits a protein known as PD-1 (programmed cell death protein 1) present in T immune cells. For example, in November 2023, Merck, an American establishment producing Keytruda, introduced KEYTRUDA (pembrolizumab) mixed with fluoropyrimidine- and platinum-containing chemotherapy, having gained approval from the Food and Drug Administration, a government agency in the US. Compelling improvements in overall survival and progression-free survival versus solo chemotherapy treatment have been observed with this combination, marking a significant leap forward in gastric cancer treatment. Clinical trials have shown this combined therapy to offer enhancements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) as compared to chemotherapy as an individual therapy.
Who Are the Key Players In The Keytruda Market?
Major companies operating in the keytruda market are:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Roche Holding AG
• Merck & Co. Inc.
• AbbVie Inc.
• Sanofi S.A.
• Novartis AG
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Amgen Inc.
• Gilead Sciences Inc.
• Teva Pharmaceutical Industries Ltd.
• Biogen Inc.
• Chugai Pharmaceutical Co. Ltd.
• BioNTech AG
• Organon Co.
• Ono Pharmaceutical Co. Ltd.
• Samsung Bioepis Co. Ltd.
• Fate Therapeutics Inc.
• Merck Sharp & Dohme Corp.
• KinBio
• Schering-Plough AB
• LGM Pharma LLC
• Gritstone Bio Inc.
What Are The Regional Insights Into The Keytruda Market?
North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
